资讯

Ophthalmology Times13 小时
Ocugen’s IND amendment to begin phase 2/3 confirmatory trial of OCU410ST cleared by FDA
Ocugen has announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to ...